Innocan Pharma's Latest Advances in CBD Treatments
Innocan Pharma Corporation is making significant strides in the field of pharmaceuticals and biotechnology with its innovative research on Synthetic Liposomal Cannabidiol (LPT-CBD). This recent study, published in a respected journal, showcases the potential of CBD as a non-opioid therapy for pain management, shedding light on its efficacy and safety profile.
Research Highlights from LPT-CBD Administration
The compelling study focuses on two goats that were administered LPT-CBD every six weeks over a span of 10 months. With each administration, a detailed assessment of the plasma concentrations of CBD and its metabolites took place, alongside evaluations of their overall health through hematological and biochemical profiling.
Effective Pain Management via Innovative Injections
The findings from this study underline the favorable outcomes associated with repeated LPT-CBD injections. They revealed:
- Consistent maintenance of CBD plasma concentrations, indicative of a slow-release pharmacokinetic profile, ensuring effective and sustained medication delivery.
- A positive tolerability profile, with no reported adverse events during the treatment period.
- Unlike traditional oral CBD treatments, LPT-CBD did not lead to elevated liver enzymes, suggesting a safer profile for long-term use.
- Significant improvements in mobility, quality of life, and pain relief, highlighting the therapeutic potential of CBD in managing chronic conditions.
Long-Term Benefits and Implications
The results of this research project not only add to the growing body of evidence on CBD but also pave the way for potential applications in human health. Innocan Pharma is at the forefront of exploring non-opioid pain relief strategies, with LPT-CBD demonstrating great promise for treating chronic pain efficiently. The extended dosing intervals and sustained relief are practical solutions for patients who require long-term management.
Expert Insights on the Study
Professor Chezy Barenholz, the Head of the Advisory Board, noted, "This study presents compelling evidence of the long-lasting beneficial effects of LPT-CBD throughout the 10-month administration period. It affirms our mission to provide innovative treatments for chronic ailments through practical administration methods."
Dr. Eyal Kalo, Vice President of Research and Development, expressed enthusiasm for the findings, stating, "This study reinforces the long-term safety and efficacy profile of LPT-CBD as a non-opioid option for chronic pain management, contrasting sharply with the risks associated with traditional CBD consumption."
About Innocan and Its Innovative Solutions
Innocan Pharma is a pioneering company focused on groundbreaking research and development in the pharmaceutical and wellness industries. They have created a sophisticated drug delivery platform utilizing CBD-loaded liposomes to ensure precise dosing and prolonged release of therapeutic agents, positioning the company as a leader in pain management solutions.
Moreover, Innocan is committed to enhancing wellness through a diverse range of self-care and beauty products. Their subsidiary, BI Sky Global Ltd., specializes in advanced online sales strategies aimed at reaching a wider audience with high-performance consumer products.
Contact Information
For further inquiries regarding Innocan Pharma Corporation, please reach out to Iris Bincovich, CEO. The contact details are as follows:
Phone: +1 5162104025
Phone: +972-54-3012842
Phone: +442037699377
Email: info@innocanpharma.com
Frequently Asked Questions
What is LPT-CBD?
LPT-CBD refers to Synthetic Liposomal Cannabidiol, a formulation designed for effective drug delivery and non-opioid pain relief.
How does the study support LPT-CBD for chronic pain management?
The study showed that LPT-CBD injections resulted in sustained pain relief and improved quality of life for the treated goats over ten months.
What are the key findings regarding safety?
No adverse events were reported during the study, and LPT-CBD did not elevate liver enzyme levels, indicating a favorable safety profile.
Can the results be applicable to humans?
While the study was conducted on goats, the results offer promising insights that may translate to human applications in pain management.
What is Innocan's focus in the wellness sector?
Innocan Pharma focuses on developing high-performance self-care and beauty products to promote healthier lifestyles, alongside its pharmaceutical innovations.
